Navigation Links
Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
Date:3/18/2013

ing OMS103HP to vehicle control in 344 patients undergoing arthroscopic partial meniscectomy surgery.  The pre-specified primary endpoint was the Symptoms Subscale of the KOOS – a patient-reported measure that is comprised of questions about knee swelling, clicking, catching and stiffness. In addition, pain measured in the early postoperative period was a pre-specified secondary endpoint. Although the Symptoms Subscale of the KOOS did not reach statistical significance, OMS103HP achieved statistically significant (p=0.0003) reduction of postoperative pain. The pain reduction data were similar in magnitude to those in the Phase 2 clinical trial. Omeros expects to conduct two concurrent Phase 3 clinical trials with reduction of early postoperative pain as the pre-specified primary endpoint and to begin enrolling patients in the first of these two planned trials in the first half of 2013. Each of these two additional Phase 3 clinical trials will enroll substantially fewer subjects than were required for the first Phase 3 trial assessing KOOS as the primary endpoint given the increased statistical power associated with reduction in early postoperative pain shown in the Phase 2 and first Phase 3 meniscectomy clinical trials.

About Omeros CorporationOmeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Be
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
2. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
3. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
4. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
5. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
6. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
7. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
8. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
9. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
10. FibeRio® Technology Corporation Announces Strategic Investment Financing Led by SABIC and Aster Capital
11. Celsion Corporation Announces $15 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Poway, CA (PRWEB) July 10, 2014 Robert ... Regenerative Veterinary Medicine company, is proud to announce the relaunch ... Pets, launching with a new series called “ What are ... to give an honest and straightforward foundation in the basics ... an educated decision on the right type of treatment when ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
(Date:7/10/2014)... , July 10, 2014  Franciscan St. ... of capnography for respiratory monitoring outside the ... healthcare leaders in embracing state-of-the-art patient safety ... patients are breathing and can alert medical ... measuring the amount of carbon dioxide the ...
(Date:7/10/2014)... 2014  Kainos Capital, a firm specializing in acquiring ... it has acquired the Slim-Fast brand from Unilever. Unilever ... of the transaction were not disclosed. Slim-Fast ... that markets ready-to-drink shakes, powders, bars and snacks to ... and in the United Kingdom ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2
... , , NATICK, Mass., ... BSX ) today announced that it has entered into ... held company offering advanced testing solutions for urinary incontinence. ... that combines staffing, equipment, supplies and results analysis, helping ...
... WEST CONSHOHOCKEN, Pa., Sept. 14 Cadient ... healthcare industry, today announced that it has been ranked on the ... companies in the country for the third consecutive year. Moving ... of this prestigious roster. The company experienced 124.3 percent growth ...
... , HOPKINTON, Mass., Sept. 14 ... leading provider of tools and services for drug discovery and ... vivo imaging system, the latest addition to the IVIS product ... fluorescence molecular optical imaging with the anatomical precision of digital ...
Cached Biology Technology:Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 2Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 3Cadient Group Ranks on Inc. 5000 List of Fastest-Growing Companies for Third Consecutive Year 2Caliper Life Sciences Launches IVIS(R) In Vivo Imaging System with X-Ray 2Caliper Life Sciences Launches IVIS(R) In Vivo Imaging System with X-Ray 3
(Date:7/11/2014)... increased risk of kidney injury related to the use ... mass of HES molecules, according to a report in ... International Anesthesia Research Society (IARS). , The "total mass ... on cultured human renal proximal tubule cells (PTCs), concludes ... of University Hospital Wrzburg, Austria. Other factorssuch as ...
(Date:7/11/2014)... that under the normal circumstances, astrocytes participate ... neuronal environment, and exhibit therapeutic and repairing ... Previous studies have found that nerve cells ... induction have reduced viability, which produces influences ... Yuan, Kailuan General Hospital, Hebei United University, ...
(Date:7/11/2014)... toxins to study the proteins that let nerve cells ... have stumbled upon a biological tactic that may offer ... in a safe and environmentally responsible way. , ... for one species and harmless for a closely related ... pests without harming beneficial species like bees. A summary ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3
... a novel H7N9 influenza virus was identified in China ... humans, resulting in some deaths. A group of scientists, ... Laboratory, State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary ... the origins of this novel H7N9 influenza virus (Shi ...
... University of Alberta researchers were certainly surprised when they ... vegetation that had previously been grazed on by caterpillars ... U of A biology researcher Isabel C. Barrio analyzed ... vegetation in alpine areas of the southwest Yukon. The ...
... with bacteria that shrug off existing antibiotics and sterilization ... of selective antimicrobial agents that do not rely on ... which can be custom-designed to recognize the shape of ... the Journal of the American Chemical Society . ...
Cached Biology News:Source identification of H7N9 influenza virus causing human infections 2Source identification of H7N9 influenza virus causing human infections 3Discovered: A mammal and bug food co-op in the High Arctic 2
Kit includes your choice of reagents for labeling 3 x 10 9 cells and EasySep magnet....
Plasmid expressing PLAP reporter gene....
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
...
Biology Products: